- | Pays :
- United Kingdom
- | Organes : -
- | Spécialités : -
Extrait
The primary objective of this study is to determine the absolute bioavailability of SRT2104 as a 250 mg suspension, and to define the intravenous pharmacokinetics of SRT2104. The secondary objective of this study is to assess the potential systemic metabolite burden of SRT2104, and to provide plasma and urine samples for subsequent metabolite profiling and identification.
Critère d'inclusion
- Diabetes Mellitus, Type 2 ,healthy volunteer